AXDX — Accelerate Diagnostics Cashflow Statement
0.000.00%
Last trade - 00:00- $13.36m
- $60.54m
- $11.70m
- 17
- 39
- 60
- 32
Annual cashflow statement for Accelerate Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -78.2 | -77.7 | -62.5 | -61.6 | -50 |
| Depreciation | |||||
| Non-Cash Items | 28.2 | 28 | 8.51 | 13.2 | 19.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.35 | -0.102 | 2.25 | 4.97 | 2.59 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -50.4 | -47.3 | -48.7 | -40.2 | -24.2 |
| Capital Expenditures | -1.36 | -0.603 | -0.554 | -1.03 | -0.509 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 15 | 8.91 | 13 | 9.7 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 13.6 | 8.3 | 12.4 | 8.66 | -0.509 |
| Financing Cash Flow Items | 0 | -1.24 | -0.192 | -3.73 | -2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 11.6 | 43.2 | 31.6 | 9.02 | 27.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -25.2 | 4.12 | -4.99 | -22.8 | 2.96 |